-
Mashup Score: 1
It was announced that the phase 3 EMBARK study met its primary end point in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
A study arm from the phase 3 EMBARK trial evaluating enzalutamide for the treatment of nmCSPC with high-risk BCR has resulted in positive patient outcomes.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Enzalutamide plus #leuprolide showed significant improvements in metastasis-free survival as a new treatment combination for nmCSPC in a study arm from the phase 3 EMBARK trial. Learn more: https://t.co/Y0jGRhqSji https://t.co/Noblu7Y5Wa
-
-
Mashup Score: 6Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design - 3 year(s) ago
Abstract Objectives This study will compare the incidence of major adverse cardiovascular events (MACEs) with androgen deprivation therapy (ADT) among men with advanced prostate cancer who are bein…
Source: JACC: CardioOncologyCategories: Cardiac Surgery, Latest HeadlinesTweet-
Watching the hot line trial on #PRONOUNCE during #ESCCongress? Check out #JACCCardioOnc's overview of the trial study design to learn more: https://t.co/n2WyYRPFRJ #CardioOnc #ASCVD #Degarelix #ProstateCancer #Leuprolide #PCsm @DukeHealth @DLBHATTMD https://t.co/fSFuS5O9Pv
-
-
Mashup Score: 1
ASCO 2021 phase 3 HERO study, relugolix demonstrated sustained testosterone suppression to castrate levels, use of relugolix in advanced prostate cancer, subgroup analysis for the HERO phase 3 trial, Michael Cookson.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Impact of age on efficacy and safety of #relugolix: a subgroup analysis from the randomized, PIII #HERO study vs #leuprolide in men with advanced #ProstateCancer. Presented by @michaelcookso18 @OUHSC_research. #ASCO21 written coverage by @zklaassen_md > https://t.co/E0mF3qwEDO https://t.co/k8D0Ys9vfI
-
-
Mashup Score: 1
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial – Moderated Discussion (20-minutes). Independent Medical Education Initiative Supported by Myovant Sciences Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina Urologic Research Center. He…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Androgen deprivation with oral #relugolix vs #leuprolide in advanced #ProstateCancer. @michaelcookso18, @CaPsurvivorship, & Neal Shore, MD, FACS discuss the #HERO trial on UroToday. #WatchNow > https://t.co/SMGXslGhUg @OUHSC_research @NUFeinbergMed @AtlanticUrology @Myovant https://t.co/n2MGX52Wiy
-
-
Mashup Score: 0Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial- Neal Shore - 3 year(s) ago
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer Lecture Presentation – Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial – Neal Shore (12-minute lecture) Independent Medical Education Initiative Supported by Myovant Sciences Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina Urologic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Androgen deprivation with oral #relugolix vs #leuprolide in advanced #ProstateCancer. Neal Shore, MD, FACS @AtlanticUrology joins @michaelcookso18 @OUHSC_research for a presentation on the #HERO trial. #WatchNow on UroToday > https://t.co/KKgYIx4cwe @Myovant https://t.co/KhwhlHl3pU
-
-
Mashup Score: 0Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In HERO, 96.7% of men who received #relugolix maintained sustained testosterone suppression to castrate levels (less than 50 ng/dL) through 48 weeks, compared with 88.8 % of men receiving #leuprolide. Read more: https://t.co/SL0m6nYuq0 #cancer #menshealth via @AtlanticUrology https://t.co/XIFRvQZkhD
-
-
Mashup Score: 3Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial- Neal Shore - 3 year(s) ago
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer Lecture Presentation – Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial – Neal Shore (12-minute lecture) Independent Medical Education Initiative Supported by Myovant Sciences Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina Urologic…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Androgen deprivation with oral #relugolix vs #leuprolide in advanced #ProstateCancer. Neal Shore, MD, FACS @AtlanticUrology joins @michaelcookso18 @OUHSC_research for a presentation on the #HERO trial. #WatchNow on UroToday > https://t.co/KKgYIx4cwe @Myovant https://t.co/CJuCESt31d
-
-
Mashup Score: 1
Contemporary Treatment Strategies For Androgen Deprivation Therapy In Prostate Cancer Androgen Deprivation With Oral Relugolix vs Leuprolide in Advanced Prostate Cancer: HERO Trial – Moderated Discussion (20-minutes). Independent Medical Education Initiative Supported by Myovant Sciences Biographies: Neal Shore, MD, FACS , is the Medical Director of the Carolina Urologic Research Center. He…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Androgen deprivation with oral #relugolix vs #leuprolide in advanced #ProstateCancer. @michaelcookso18, @CaPsurvivorship, & Neal Shore, MD, FACS discuss the #HERO trial on UroToday. #WatchNow > https://t.co/SMGXslGhUg @OUHSC_research @NUFeinbergMed @AtlanticUrology @Myovant https://t.co/Jl2v7HPwX2
-
-
Mashup Score: 1Wolters Kluwer Health - 3 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable…
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In HERO, 96.7% of men who received #relugolix maintained sustained testosterone suppression to castrate levels (less than 50 ng/dL) through 48 weeks, compared with 88.8 % of men receiving #leuprolide. Read more: https://t.co/SL0m6og5hy #cancer #menshealth via @AtlanticUrology https://t.co/sUPF5AAEu9
-
Patients with #nmCSPC who received #enzalutamide + #leuprolide had a lower risk of metastasis or death vs those who did not receive enzalutamide. @GenesisCare | #pcsm https://t.co/Rcz99y3FYX